Latest news with #MarksansPharma
News18
3 days ago
- Business
- News18
Unifi Capital sells 1.6 pc stake in Marksans Pharma for nearly Rs 168 cr
Agency: New Delhi, Jul 28 (PTI) Investment management company Unifi Capital on Monday sold a 1.6 per cent stake in Marksans Pharma for nearly Rs 168 crore through an open market transaction. According to the bulk deal data on the BSE, Chennai-based Unifi Capital Pvt Ltd offloaded 72.41 lakh equity shares or 1.6 per cent stake in Marksans Pharma. The shares were disposed of at an average price of Rs 231.50 apiece, taking the transaction value to Rs 167.63 crore. Details of the buyers of Mumbai-based Marksans Pharma's shares could not be ascertained on the exchange. Shares of Marksans Pharma slipped 0.68 per cent to close at Rs 226.45 apiece on the BSE. PTI HG HG SHW First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
07-07-2025
- Business
- Business Standard
Stocks to buy today: CCL Products, Marksans Pharma; check target, stop-loss
Stocks to buy today: CCL Products (India) has shown renewed growth in the last couple of weeks, while Marksans Pharma has experienced a gradual resurgence over the last couple of trading sessions Top stocks to buy: NSE Scrip – CCL View - Bullish Last close – ₹884.95 CCL Products (India) has shown renewed growth in the last couple of weeks, hovering in a cycle of higher highs – higher lows. This surge has been accompanied by several key developments, starting with a reversal from the breakout neckline on weekly chart structure to a V-shaped recovery, which suggests that market interest is building and points to the possibility of continuation in its trend. Additionally, the ADX indicator highlights strength in both daily and weekly chart structures, adding a bullish bias. NSE Scrip – MARKSANS View - Bullish Last close – ₹263.05 Marksans Pharma has experienced a gradual resurgence over the last couple of trading sessions, resulting in a strong weekly close. The counter is firmly positioned above all its short-term EMAs on the daily time frame structure after an extended period, suggesting inherent strength, and is expected to continue in the same manner in the near term. Additionally, the counter has witnessed an 'Inverted H&S' breakout and is backed by a positive crossover on the MACD from its signal line, aligning to the ongoing momentum.
Business Standard
30-06-2025
- Business
- Business Standard
Marksans Pharma rises after subsidiary gets EIR for New York-based facility from US FDA
Marksans Pharma advanced 1.86% to Rs 257 after the company's subsidiary Time-Cap Laboratories Inc. has received the establishment inspection report from the US FDA for its manufacturing facility based in New York. In April this year, the United States Food and Drug Administration (US FDA) had conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of Time-Cap Laboratories, Inc. located at Michael Avenue, Farmingdale, New York, USA. The inspection was conducted between 16th and 24th of April 2025. Post the said inspection, the American drug regulator had issued one inspectional observation in Form 483. There was no data integrity observation. In a regulatory filing made during market hours today, Marksans Pharma stated that Time-Cap Laboratories has received the establishment inspection report (EIR) from the US FDA for the said facility. Marksans Pharma is engaged in research, manufacturing & marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies, including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, anti-diabetic, pain management, gastroenterological, and antiallergic. The company is marketing these products globally. The company reported a 15.7% increase in consolidated net profit to Rs 90.55 crore on a 26.5% rise in revenue from operations to Rs 708.46 crore in Q4 FY25 over Q4 FY24.
Business Standard
30-06-2025
- Business
- Business Standard
Time-Cap Laboratories successfully concludes USFDA inspection
Marksans Pharma announced that its subsidiary, Time-Cap Laboratories Inc. has received the Establishment Inspection Report from USFDA. The USFDA had conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at Farmingdale, New York, USA from 16 April 2025 to 24 April 2025.
Business Upturn
30-06-2025
- Business
- Business Upturn
Marksans Pharma receives EIR from USFDA for Time-Cap Labs facility
By Aman Shukla Published on June 30, 2025, 12:33 IST Marksans Pharma has announced a positive update regarding its US operations. The company shared that its wholly owned subsidiary, Time-Cap Laboratories Inc., based in Farmingdale, New York, has successfully received the Establishment Inspection Report (EIR) from the USFDA. This follows a routine cGMP (current Good Manufacturing Practices) inspection that took place from April 16 to April 24, 2025. The inspection covered the site's compliance with quality standards, and the EIR indicates a satisfactory outcome. For those unfamiliar, Marksans Pharma is a Mumbai-headquartered pharmaceutical company that specializes in research, manufacturing, and global marketing of generic medicines. Its facilities are approved by top global regulators like the USFDA, UKMHRA, and Australia's TGA. The company's product lineup spans key therapeutic areas, including cardiovascular, central nervous system, diabetes care, pain relief, gastrointestinal health, and allergy treatment—and it's actively selling these in markets around the world. This USFDA approval reinforces Marksans Pharma's commitment to maintaining high-quality standards and its steady expansion in regulated markets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
